Revenue by source
Brands$9.18BGenerics$5.07BComplex GX and Biosimilars$0.00
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Brands | $5.23B | $10.84B | $9.89B | $9.80B | $9.20B | $9.18B |
| Generics | $5.29B | $5.63B | $5.02B | $5.59B | $5.49B | $5.07B |
| Complex GX and Biosimilars | $1.30B | $1.34B | $1.31B | - | - | - |
Revenue by country
Developed Markets Segment$8.55BEmerging Markets Segment$2.22BGreater China Segment$2.33BJapan, Australia and New Zealand Segment$1.20B
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Developed Markets Segment | $8.51B | $10.43B | $9.77B | $9.25B | $8.96B | $8.55B |
| Emerging Markets Segment | $1.85B | $3.14B | $2.62B | $2.55B | $2.26B | $2.22B |
| Greater China Segment | $259.90M | $2.21B | $2.20B | $2.16B | $2.17B | $2.33B |
| Japan, Australia and New Zealand Segment | $1.20B | $2.03B | $1.63B | $1.42B | $1.35B | $1.20B |